Richard Gonzalez, AP Images

House com­mit­tee un­cov­ers how Hu­mi­ra’s price spiked by 470% as Ab­b­Vie ex­ecs cashed bonus­es tied to the hikes

Pri­or to the House Com­mit­tee on Over­sight’s grilling of Ab­b­Vie CEO Richard Gon­za­lez on Tues­day, the com­mit­tee staff re­leased a 57-page re­port fol­low­ing a two year in­ves­ti­ga­tion in­to how and why the com­pa­ny spiked the price of Hu­mi­ra (adal­i­mum­ab) and made it the high­est-gross­ing drug of all time.

While the com­mit­tee in­ves­ti­ga­tion and pub­lic lash­ing aren’t like­ly to do ac­tu­al dam­age to Ab­b­Vie’s bot­tom line or bring new Hu­mi­ra biosim­i­lar com­pe­ti­tion be­fore 2023 in the US, the re­port digs in­to how Ab­b­Vie used more than two dozen price in­creas­es, shad­ow pric­ing with Am­gen’s block­buster En­brel, and patent thick­ets to block com­pe­ti­tion while amass­ing more than $170 bil­lion in net rev­enue from Hu­mi­ra since 2003.

Reps. Car­olyn Mal­oney (D-NY), chair of the Over­sight Com­mit­tee, Jar­rold Nadler (D-NY), chair of the House Ju­di­cia­ry Com­mit­tee, and sub­com­mit­tee chair David Ci­cilline (D-RI) al­so sent a let­ter to the Fed­er­al Trade Com­mis­sion on Tues­day, call­ing for a for­mal in­quiry in­to Ab­b­Vie’s ac­tions to de­lay the en­try of Hu­mi­ra biosim­i­lars in the US (more on the de­lays be­low).

Price In­creas­es

Near­ly a decade af­ter Ab­bott Lab­o­ra­to­ries first launched Hu­mi­ra in 2003, the list price rose from $522 per 40-mil­ligram sy­ringe to $1,024 by 2013, with 13 price hikes, pri­or to spin­ning off Ab­b­Vie as a sep­a­rate com­pa­ny. Un­der Ab­b­Vie, the price of Hu­mi­ra spiked an­oth­er 14 times, in­clud­ing by 30% with­in a 10-month win­dow.

“Hu­mi­ra is now priced at $2,984 per sy­ringe, or $77,586 an­nu­al­ly — a 470% in­crease from when the drug en­tered mar­ket,” the re­port says.

And those con­sis­tent price hikes were dri­ven by ex­ec­u­tive bonus­es from 2015 to 2018, which were di­rect­ly linked to Hu­mi­ra’s fi­nan­cial per­for­mance, the re­port says.

In that first year that the in­cen­tives were cre­at­ed, ex­ecs pushed Hu­mi­ra’s US net rev­enue to rise from $6.5 bil­lion in 2014 to $8.4 bil­lion in 2015, af­ter Ab­b­Vie ex­ec­u­tives im­ple­ment­ed a 9.9% price in­crease in April 2015 — the largest-ever price in­crease for the drug — and a 7.9% price in­crease in Au­gust 2015.

While Gon­za­lez will like­ly tell Con­gress Tues­day that the price in­creas­es were used to fund more re­search & de­vel­op­ment, the com­mit­tee shows that wasn’t the case.

“Ab­b­Vie’s to­tal re­search and de­vel­op­ment ex­pen­di­tures for Hu­mi­ra rep­re­sent­ed on­ly a small frac­tion of its net rev­enue from this drug. In re­sponse to the Com­mit­tee’s re­quest, Ab­b­Vie iden­ti­fied a to­tal of $5.19 bil­lion in ‘Hu­mi­ra Re­search & De­vel­op­ment’ be­tween 2009 and 2018 — ap­prox­i­mate­ly 7.4% of its Hu­mi­ra U.S. net rev­enue and 4.2% of its Hu­mi­ra world­wide net rev­enue over that pe­ri­od,” the re­port shows.

What the US would’ve saved

The re­port al­so tracks how much the US gov­ern­ment could’ve saved over­all by fac­tor­ing in some of the dis­counts that some fed­er­al de­part­ments re­ceive. Over­all, Ab­b­Vie’s Hu­mi­ra net rev­enue from Medicare — a fig­ure that sub­tracts dis­counts and re­bates— was $9.9 bil­lion from 2010 to 2018.

“If Medicare had re­ceived the same dis­counts as the De­part­ment of De­fense, it would have saved more than $7.4 bil­lion on Hu­mi­ra from 2010 to 2018. Sim­i­lar­ly, if Medicare had re­ceived the same dis­counts as the De­part­ment of Vet­er­ans Af­fairs, it would have saved $7 bil­lion on Hu­mi­ra from 2010 to 2018,” the re­port notes.

Re­pub­li­cans in Con­gress have fo­cused their at­ten­tion less on low­er­ing drug prices and more on low­er­ing out-of-pock­et costs, the re­port re­veals how out-of-pock­et costs for Hu­mi­ra have spiked too.

A 2019 Kaiser Fam­i­ly Foun­da­tion study found that the me­di­an an­nu­al out-of-pock­et cost for Medicare pa­tients on Hu­mi­ra was $5,471 in 2019, which is $606 more than in 2016.

A re­tired teacher and Medicare ben­e­fi­cia­ry with Crohn’s dis­ease told the com­mit­tee that de­spite hav­ing a sup­ple­men­tal health in­sur­ance plan, her out-of-pock­et costs for Hu­mi­ra were more than $2,600 for a month’s sup­ply, pre­vent­ing her from re­ceiv­ing treat­ment.

Rock­ford, Illi­nois May­or Tom Mc­Na­ma­ra al­so re­port­ed that be­tween Au­gust 2013 and Ju­ly 2020, his city spent more than $2.5 mil­lion on Hu­mi­ra alone, which means more than 5% of the city’s em­ploy­ee health plan ex­pen­di­tures were for Hu­mi­ra.

Don’t blame the play­er, blame the game?

In ad­di­tion to rais­ing the price, Ab­b­Vie al­so halt­ed any po­ten­tial com­pe­ti­tion un­til 2023 (de­spite the launch of Hu­mi­ra biosim­i­lars in Eu­rope in 2018), and that sup­pres­sion oc­curred even be­yond Ab­b­Vie’s own in­ter­nal pro­jec­tions.

In Feb­ru­ary 2014, ac­cord­ing to the com­mit­tee re­port, Ab­b­Vie ex­ec­u­tives cir­cu­lat­ed a pre­sen­ta­tion on “US Hu­mi­ra Biosim­i­lar Ero­sion” that pro­ject­ed that three to five biosim­i­lar com­peti­tors would en­ter the mar­ket by the first quar­ter of 2017.

What’s more, Ab­b­Vie’s patent on Hu­mi­ra’s ac­tive in­gre­di­ent ex­pired on De­cem­ber 31, 2016.

“At that time, com­peti­tors should have been free to en­ter the mar­ket. How­ev­er, the com­pa­ny ex­ploit­ed the patent sys­tem to ob­tain or ap­ply for over 200 ad­di­tion­al patents on Hu­mi­ra to block biosim­i­lar com­pe­ti­tion,” the re­port says.

Am­gen’s block­buster bi­o­log­ic En­brel, which won’t see biosim­i­lar com­pe­ti­tion in the US un­til 2029, is al­so one of Hu­mi­ra’s top com­peti­tors, and the com­mit­tee showed how the two com­pa­nies raised the prices of their drugs in lock-step with each oth­er.

“In­ter­nal Ab­b­Vie doc­u­ments ob­tained by the Com­mit­tee re­veal that the com­pa­ny viewed Am­gen’s price in­creas­es as pro­vid­ing cov­er for its own price in­creas­es. For ex­am­ple, one com­pa­ny ex­ec­u­tive re­port­ed to the cur­rent CEO and then-Ex­ec­u­tive Vice Pres­i­dent Richard Gon­za­lez that it was a ‘Great week-end’ af­ter learn­ing that Am­gen had in­creased the price of En­brel on Jan­u­ary 20, 2012, to $25,150 an­nu­al­ly. The email thread not­ed that ear­li­er that month, Ab­b­Vie had in­creased the price of Hu­mi­ra to $24,913 an­nu­al­ly. In Ju­ly, Ab­b­Vie would top Am­gen again by rais­ing the price of Hu­mi­ra to $26,632. Less than 3 weeks lat­er, Am­gen fol­lowed suit with an­oth­er price in­crease,” the re­port says.

Op­ti­miz­ing Cell and Gene Ther­a­py De­vel­op­ment and Pro­duc­tion: How Tech­nol­o­gy Providers Like Corn­ing Life Sci­ences are Spurring In­no­va­tion

Remarkable advances in cell and gene therapy over the last decade offer unprecedented therapeutic promise and bring new hope for many patients facing diseases once thought incurable. However, for cell and gene therapies to reach their full potential, researchers, manufacturers, life science companies, and academics will need to work together to solve the significant challenges facing the industry.

David Baker working with a student on their protein design (Jason Mast)

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

SEATTLE — It’s a cloudy Thursday afternoon in mid-July and David Baker is reclining into the futon in his corner office at the University of Washington, arms splayed out like a daytime talk show host as he coaches another one of his postdocs through the slings and arrows of scientific celebrity.

“Be jealous of your time,” he says, before plotting ways of sneaking her out of Zooms. “It’s this horrible cost to science that you’re tied up in some stupid meeting.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Patty Murray, D-WA (Graeme Sloan/Sipa USA)(Sipa via AP Images)

Sen­ate user fee reau­tho­riza­tion bill omits ac­cel­er­at­ed ap­proval re­forms, shows wide gaps with House ver­sion

The Senate health committee on Tuesday released its first version of the bill to reauthorize all the different FDA user fees. But unlike the House version, there are only a few controversial items in the Senate’s version, which does not address either accelerated approval reforms or clinical trial diversity (as the House did).

While it’s still relatively early in the process of finalizing this legislation (the ultimate statutory deadline is the end of September), the House and Senate, at least initially, appear to be starting off in different corners on what should be included.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.

Pre­sent­ing a live End­points News event: Man­ag­ing a biotech in tur­bu­lent times

Biotech is one of the smartest, best educated industries on the planet. PhDs abound. We’ve had a long enough track record to see a new generation of savvy, experienced execs coming together to run startups.

And in these times, they are being tested as never before.

Biotech is going through quite a rough patch right now. For 2 years, practically anyone with a decent resume and some half-baked ideas on biotech could start a company and get it funded. The pandemic made it easy in many ways to pull off an IPO, with traditional road shows shut down in exchange for a series of quick Zoom meetings. Generalist investors flocked as the numbers raised soared into the stratosphere.

Warren Buffett, Berkshire Hathaway CEO

Berk­shire Hath­away pulls out of Ab­b­Vie, Bris­tol My­ers Squibb in­vest­ments

It looks like Warren Buffett is sticking to ice cream and railroads for the moment.

The billionaire CEO of Berkshire Hathaway backed out of two major holdings in the pharma industry, Forexlive first reported, including a $410 million investment in AbbVie and a $324.4 million stake in Bristol Myers Squibb.

The move comes after Berkshire abandoned its Teva shares just last quarter, Bloomberg reported.

Long-ex­pect­ed UK lay­offs im­mi­nent for No­var­tis fol­low­ing sale

Nearly a year ago, more than 200 workers at Novartis’ Grimsby, UK, facility were able to hang on to their jobs after the pharma closed a Switzerland site as a part of its workforce restructuring plan. Now, it looks like those employees’ time is up, as the site has been sold, Grimsby Telegraph reported today.

The manufacturing site has been sold to Humber Industrials, a subsidiary of International Process Plants. None of the current staff members will be working with the new owners, however.

Pri­cy in­halers re­main ex­pen­sive due to de­vice tweaks that keep com­peti­tors at bay, re­searchers find

New research published in Health Affairs today highlights the way in which the FDA’s inhaler regulations have rewarded incremental adjustments to older products, thereby enabling companies to skirt around cheaper competition.

A DC appeals court clerk and researchers from Harvard and the University of Calgary dug through all the patents and regulatory exclusivities granted to inhalers approved by the FDA between 1986 and 2020, finding that of the 62 inhalers approved, 53 (or 85%) were brand-name products, with a median of 16 years of protection from generic competition.

FDA lob­bies Con­gress over rare dis­ease court rul­ing with wide im­pli­ca­tions

Usually reserved for making decisions on drug applications or enforcing what Congress stipulates, the FDA is now dipping its toe into the wild world of congressional politics as it attempts to fix a major court decision that could have a chilling effect on rare disease R&D.

The case in question from last October saw a US appeals court overturn a prior FDA court win, saying that the agency never should’ve approved a rare disease drug because a previously approved but more expensive drug with the same active ingredient has orphan drug exclusivity barring such an approval.

Peter Marks (Greg Nash/Pool via AP)

Even FDA's Pe­ter Marks is wor­ried about the com­mer­cial vi­a­bil­i­ty of gene and cell ther­a­pies

When bluebird bio’s gene therapy to treat beta thalassemia won European approval in 2019, the nearly $2 million per patient price tag for the potential cure seemed like a surmountable hurdle.

Fast forward two years later, and bluebird has withdrawn Zynteglo, the beta thal drug, along with the rest of its gene therapy portfolio from Europe, which the company said is generally unwilling to pay a fair price for the treatment.